Humacyte Inc [NASDAQ: HUMA] closed the trading session at $1.25 on 2025-11-12. The day’s price range saw the stock hit a low of $1.22, while the highest price level was $1.43.
The stocks have a year to date performance of -78.37 percent and weekly performance of -13.79 percent. The stock has been moved at -33.16 percent over the last six months. The stock has performed -30.17 percent around the most recent 30 days and changed -33.51 percent over the most recent 3-months.
If compared to the average trading volume of 5.07M shares, HUMA reached to a volume of 8132846 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Humacyte Inc [HUMA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HUMA shares is $8.29 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HUMA stock is a recommendation set at 1.43. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for Humacyte Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 27, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on May 14, 2025, representing the official price target for Humacyte Inc stock. Previously, the target price had yet another raise from $12 to $15, while H.C. Wainwright kept a Buy rating on HUMA stock.
The Price to Book ratio for the last quarter was 48.23, with the Price to Cash per share for the same quarter was set at 0.10.
HUMA stock trade performance evaluation
Humacyte Inc [HUMA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.79. With this latest performance, HUMA shares dropped by -30.17% in over the last four-week period, additionally sinking by -33.16% over the last 6 months – not to mention a drop of -75.25% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HUMA stock in for the last two-week period is set at 33.32, with the RSI for the last a single of trading hit 0.1283, and the three-weeks RSI is set at 0.1401 for Humacyte Inc [HUMA]. The present Moving Average for the last 50 days of trading for this stock 1.6367, while it was recorded at 1.3040 for the last single week of trading, and 2.2118 for the last 200 days.
Humacyte Inc [HUMA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Humacyte Inc [HUMA] shares currently have an operating margin of -6708.40% and a Gross Margin at 60.53%. Humacyte Inc’s Net Margin is presently recorded at -2504.33%.
Humacyte Inc (HUMA) Capital Structure & Debt Analysis
According to recent financial data for Humacyte Inc. ( HUMA), the Return on Equity (ROE) stands at -257.38%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -38.15%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Humacyte Inc’s Return on Invested Capital (ROIC) is -98.17%, showcasing its effectiveness in deploying capital for earnings.
Humacyte Inc (HUMA) Efficiency & Liquidity Metrics
Humacyte Inc (HUMA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Humacyte Inc. (HUMA) effectively leverages its workforce, generating an average of -$178818.18 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.62% and a Quick Ratio of 0.90%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Humacyte Inc [HUMA] stock
With the latest financial reports released by the company, Humacyte Inc posted -0.21/share EPS, while the average EPS was predicted by analysts to be reported at -0.25/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.05. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HUMA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Humacyte Inc go to 47.15%.
Humacyte Inc [HUMA]: Institutional Ownership
There are presently around $29.22%, or 35.18%% of HUMA stock, in the hands of institutional investors. The top three institutional holders of HUMA stocks are: BLACKROCK INC. with ownership of 7.14 million shares, which is approximately 5.9912%. VANGUARD GROUP INC, holding 4.73 million shares of the stock with an approximate value of $$22.7 million in HUMA stocks shares; and VANGUARD GROUP INC, currently with $$13.77 million in HUMA stock with ownership which is approximately 2.4071%.
